A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study

Amantadine has begun to be used as a possible alternative in COVID-19 therapy to mitigate its effects. There is anecdotal evidence that patients with Parkinson's disease (PD) treated with amantadine and who test positive for COVID-19 often do not develop clinical manifestations of COVID-19.
Objective: to compare the clinical course of COVID-19 in patients with PD who took or did not take amantadine sulfate.
Patients and methods. A prospective continuous study included 142 patients with PD who were treated in Republican Clinical Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy in Kazan from October 2021 to January 2022. Patients filled out a proprietary internally developed questionnaire.
Results and discussion. Out of 142 individuals with PD COVID-19 occurred in 77 (54.2%), of which 52.0% had a mild course, 39.0% had a moderate course, 2.6% had a severe course, and in 6.5% the severity of the disease has not been established. Deterioration after COVID-19 infection was noted by 36% of patients: the appearance or increase in motor fluctuations (41%), increased tremor, stiffness or slowness (31%), the appearance of "exhaustion" of the effect of a single dose of levodopa (13%), the appearance or increased dyskinesia (21%), hallucinations (3.5%). Patients taking amantadine sulfate had PD much longer (11.5±5.62 years versus 5.12±3.24 years) and had a more pronounced (III–IV) stage of the disease. These patients were more likely to experience mild COVID-19 (in 60.87% of cases), in contrast to patients not receiving amantadine sulfate (only in 48.15% of cases). There was no correlation between the severity of COVID-19 and levodopa intake.
Conclusion. The results of the study showed that patients with PD taking amantadine sulfate are more likely to have a mild course of COVID-19.

1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020 Mar 19;91(1):157-60. doi:10.23750/abm.v91i1.9397

2. RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030-40. doi:10.1056/NEJMoa2022926. Epub 2020 Oct 8.

3. Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. doi:10.1186/s12941-020-00368-w

4. Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020 Jun;582(7813):469. doi:10.1038/d41586-020-01824-5

5. Choi SW, Shin JS, Park SJ, et al. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Res. 2020 Dec;184:104955. doi:10.1016/j.antiviral.2020.104955. Epub 2020 Oct 19.

6. Kim A, Gandhi R. Coronavirus disease 2019 (COVID-19): management in hospitalized adults. UpToDate. 2020.

7. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020 Jul;42:102163. doi:10.1016/j.msard.2020.102163. Epub 2020 Apr 30.

8. Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. Int J Antimicrob Agents. 2020 Jun;55(6):106004. doi:10.1016/j.ijantimicag.2020.106004. Epub 2020 Apr 30.

9. Abreu GEA, Aguilar MEH, Covarrubias DH, et al. Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. 2020 Jul;140:109755. doi:10.1016/j.mehy.2020.109755. Epub 2020 Apr 25.

10. McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res. 2016 May;129:21-38. doi:10.1016/j.antiviral.2016.01.012. Epub 2016 Feb 9.

11. Katunina EA. Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(4):101-6. doi:10.17116/jnevro2021121041101 (In Russ.).

12. Helmich RC, Bloem BR. The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities. J Parkinsons Dis. 2020;10(2):351-4. doi:10.3233/JPD-202038

13. Djamshidian A, Lees AJ. Can stress trigger Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):878-81. doi:10.1136/jnnp-2013-305911. Epub 2013 Nov 20.

14. Snyder AM, Stricker EM, Zigmond MJ. Stress-induced neurological impairmentsin an animal model of parkinsonism. Ann Neurol. 1985 Nov;18(5):544-51. doi:10.1002/ana.410180506

15. Zalyalova ZA, Khasanova DM. Risk and course of COVID-19 in patients with Parkinson’s disease. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(9):152-6. doi:10.17116/jnevro2021121091152 (In Russ.).

16. Meng L, Qiu H, Wan L, et al. Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan's Experience. Anesthesiology. 2020 Jun;132(6):1317-32. doi:10.1097/ALN.0000000000003296

17. Bhidayasiri R, Virameteekul S, Kim JM, et al. COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson's Disease Patient Care. J Mov Disord. 2020 May;13(2):105-14. doi:10.14802/jmd.20042. Epub 2020 Apr 30.

18. Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's Disease Patients Affected by COVID-19. Mov Disord. 2020 Jun;35(6):905-8. doi:10.1002/mds.28104. Epub 2020 May 28.

19. Yamschikova NG, Stavrovskaya AV, Illarioshkin SN. Some aspects of neurodegenerative diseases. Asimmetriya. 2018;12(4):631-8 (In Russ.).

20. Massey AR, Beckham JD. Alpha-synuclein, a novel viral restriction factor hiding in plain sight. DNA Cell Biol. 2016;35(11):643-5. doi:10.1089/dna.2016.3488

21. Labrie V, Brundin P. Alpha-synuclein to the rescue: Immune cell recruitment by alpha-synuclein during gastrointestinal infection. J Innate Immun. 2017;9(5):437-40. doi:10.1159/000479653. Epub 2017 Sep 2.

22. Xiao W, Shameli A, Harding CV, et al. Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson’s disease. Immunobiology. 2014;219:836-44. doi:10.1016/j.imbio.2014.07.014

23. AitWahmane S, Achbani A, Ouhaz Z, et al. The Possible Protective Role of α-Synuclein against Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Patients With Parkinson's Disease. Mov Disord. 2020 Aug;35(8):1293-4. doi:10.1002/mds.28185. Epub 2020 Jul 16.

24. Fearon C, Fasano A. Parkinson's Disease and the COVID-19 Pandemic. J Parkinsons Dis. 2021;11(2):431-44. doi:10.3233/JPD-202320

25. Bone NB, Liu Z, Pittet J-F, et al. Frontline Science: D1 dopaminergic receptor signaling activates the AMPK-bioenergetic pathway in macrophages and alveolar epithelial cells and reduces endotoxin-induced ALI. J Leukoc Biol. 2017 Feb;101(2):357-65. doi:10.1189/jlb.3HI0216-068RR. Epub 2016 Oct 12.

26. Zheng KS, Dorfman BJ, Christos PJ, et al. Clinical characteristics of exacerbations in Parkinson disease. Neurologist. 2012 May;18(3):120-4. doi:10.1097/NRL.0b013e318251e6f2

27. Brugger F, Erro R, Balint B, et al. Why is there motor deterioration in Parkinson's disease during systemic infections – a hypothetical view. NPJ Parkinsons Dis. 2015 Aug 27;1:15014. doi:10.1038/npjparkd.2015.14

28. Umemura A, Oeda T, Tomita S, et al. Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study. PLoS One. 2014 Jun 2;9(6):e94944. doi:10.1371/journal.pone.0094944

29. Artusi CA, Romagnolo A, Imbalzano G, et al. COVID-19 in Parkinson's disease: Report on prevalence and outcome. Parkinsonism Relat Disord. 2020 Nov;80:7-9. doi:10.1016/j.parkreldis.2020.09.008. Epub 2020 Sep 6.

30. Zach H, Dirkx MF, Pasman JW, et al. Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor. CNS Neurosci Ther. 2017 Mar;23(3):209-15. doi:10.1111/cns.12670. Epub 2017 Jan 10.

31. Macht M, Kaussner Y, Moller JC, et al. Predictors of freezing in Parkinson’s disease: A survey of 6,620 patients. Mov Disord. 2007;22:953-6. doi:10.1002/mds.21458

32. Ehgoetz Martens KA, Hall JM, Georgiades MJ, et al. The functional network signature of heterogeneity in freezing of gait. Brain. 2018;141(4):1145-60. doi:10.1093/brain/awy019

33. Cilia R, Bonvegna S, Straccia G, et al. Effects of COVID-19 on Parkinson's Disease Clinical Features: A Community-Based CaseControl Study. Mov Disord. 2020 Aug;35(8):1287-92. doi:10.1002/mds.28170. Epub 2020 Jun 11.

34. Santos-Garcia D, Oreiro M, Perez P, et al. Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross-Sectional Survey of 568 Spanish Patients. Mov Disord. 2020 Oct;35(10):1712-6. doi:10.1002/mds.28261. Epub 2020 Sep 22.

35. Schirinzi T, Cerroni R, Di Lazzaro G, et al. Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy. Neurol Sci. 2020 Jun;41(6):1373-5. doi:10.1007/s10072-020-04442-1. Epub 2020 May 3.

36. Salari M, Zali A, Ashrafi F, et al. Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID-19) Pandemic. Mov Disord. 2020 Jul;35(7):1095-6. doi:10.1002/mds.28116. Epub 2020 May 21.

37. Prasad S, Holla VV, Neeraja K, et al. Parkinson's Disease and COVID-19: Perceptions and Implications in Patients and Caregivers. Mov Disord. 2020 Jun;35(6):912-4. doi:10.1002/mds.28088. Epub 2020 May 8.

38. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https://covid19.who.int/

39. Shalash A, Roushdy T, Essam M, et al. Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic. Mov Disord. 2020 Jul;35(7):1097-9. doi:10.1002/mds.28134. Epub 2020 Jun 7.

40. Kintz N, Petzinger GM, Jakowec MW. Treadmill exercise modifies dopamine receptor expression in the prefrontal cortex of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of Parkinson's disease. Neuroreport. 2017 Oct 18;28(15):987-95. doi:10.1097/WNR.0000000000000865

41. Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020 Apr 29;8:152. doi:10.3389/fpubh.2020.00152

42. Zalyalova ZA, Munasipova SE, Khasanova DM, et al. Parkinson's disease and COVID-19: a new role for amantadines. Results of own comparative research. Byulleten' Natsional'nogo obshchestva po izucheniyu bolezni Parkinsona i rasstroystv dvizheniy. 2022;(2):66-71 (In Russ.).

43. Cortes Borra A. Does amantadine have a protective effect against COVID-19? Neurol Neurochir Pol. 2020;54(3):284-5. doi:10.5603/PJNNS.a2020.0041. Epub 2020 Jun 4.

44. Aranda-Abreu GE, Aranda-Martinez JD, Araujo R. Use of amantadine in a patient with SARS-CoV-2. J Med Virol. 2020;93(1):110-1. doi:10.1002/jmv.26179